Stable Liquid IL-1 Antagonist Formulations
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsDaniel Dix, Katherine Bowers, Chimanlall Goolcharran, Leu-Fen H. Lin
Life of this patent
Estimating the term…
Abstract
Formulations of an interleukin-1 (IL-1) antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the IL-1 antagonist is an IL-1 trap composed of a dimer of two fusion proteins having an amino acid sequence of SEQ ID NO: 10. Stable liquid formulations made with and without sodium chloride, and made with phosphate or histidine buffer, are provided.
Claims18
A stable liquid formulation, comprising:
- histidine at 40 mM, 3% PEG, 1% glycine, 50 mM arginine, 2% sucrose, and 10-100 mg/ml IL-1 trap that is a dimeric fusion protein comprising amino acid sequence SEQ ID NO:10, wherein the formulation has a pH of about 6.5.
A stable liquid formulation, comprising:
- sodium phosphate at 40 mM, 3% PEG, 1% glycine, 50 mM arginine, 2% sucrose, and 10-100 mg/ml IL-1 trap that is a dimeric fusion protein comprising amino acid sequence SEQ ID NO:10, wherein the formulation has a pH of about 6.5.
A stable liquid formulation, comprising:
- sodium phosphate at 10 mM, 50 mM NaCl, 3% PEG, 20% sucrose, and 10-100 mg/ml IL-1 trap that is a dimeric fusion protein comprising amino acid sequence SEQ ID NO:10, wherein the formulation has a pH of about 6.5.
Dependencies are inferred from the claim text.